Introduction: Ovarian cancer is a very fatal gynecologic tumor that is often diagnosed at late stages, hence reducing the availability of other treatment methods. Naturally occurring polyphenolic compounds, isolated in botanical sources and named Flavonoids, have already shown significant promise as anticancer agents because of their ability to prevent tumor growth, cause apoptosis, and alter critical signaling pathways with minimal toxicity and wide availability. Methods: The review is an in-depth analysis of recent studies that aim at synthesizing and assessing flavonoid derivatives in the context of ovarian cancer. A scientific search and survey were conducted in key scientific databases to locate the literature on the topic used the following search words: ovarian cancer and flavonoid derivatives. The discussion primarily focused on chemical synthesis, biological efficacy, and structure-activity relationship (SAR) of these compounds. Results: Many synthetic flavonoid derivatives, in particular triazole-linked, chalcone-based, and halogenated analogs, have exhibited high cytotoxic activity against ovarian cancer cell lines (IC 50 <10μM). The production of reactive oxygen species (ROS), Topoisomerase II alpha inhibition, and the regulation of the PI3K/Akt and NF-κB signaling pathways were identified as the possible mechanistic pathways. Apigenin-7-methyl ether analogues and chrysin hybrids are among the more active and selective derivatives. Discussion: Flavonoid analogues exhibit anticancer effects by a variety of mechanisms, such as induction of apoptosis, cell-cycle arrest, and oxidative stress regulation. The SAR studies showed that certain replacements, like trifluoromethyl and halogen, and piperazine groups, improve bioactivity and drug-like properties. Synthetic methodologies usually comply with green chemistry guidelines, but additional optimization is necessary to support the development of environmental sustainability and scalability. Conclusion: Flavonoid derivatives are a promising, low-toxicity alternative/complement to traditional ovarian-cancer treatments. Although there have been preclinical successes, issues like poor bioavailability and lack of in vivo validation still remain. Interdisciplinary studies are urgently required so that these compounds can be translated into therapeutic interventions that can be used in clinical practice.
Thombre et al. (Mon,) studied this question.